Radiotherapy for renal-cell carcinoma

被引：252

作者：

De Meerleer, Gert ^{[1
]}

Khoo, Vincent ^{[3
]}

Escudier, Bernard ^{[4
]}

Joniau, Steven ^{[6
]}

Bossi, Alberto ^{[5
]}

Ost, Piet ^{[1
]}

Briganti, Alberto ^{[7
]}

Fonteyne, Valerie ^{[1
]}

Van Vulpen, Marco ^{[8
]}

Lumen, Nicolaas ^{[2
]}

Spahn, Martin ^{[9
]}

Mareel, Marc ^{[1
]}

机构：

[1] Ghent Univ Hosp, Dept Radiat Oncol & Expt Canc Res, B-9000 Ghent, Belgium

[2] Ghent Univ Hosp, Dept Urol, B-9000 Ghent, Belgium

[3] Royal Marsden NHS Fdn Trust, Dept Clin Oncol, London, England

[4] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France

[5] Inst Gustave Roussy, Dept Radiat Oncol, Villejuif, France

[6] Univ Hosp Leuven, Dept Urol, Louvain, Belgium

[7] Univ Vita Salute San Raffaele, Dept Urol, Milan, Italy

[8] Univ Med Ctr Utrecht, Radiat Dept, Utrecht, Netherlands

[9] Univ Hosp Bern, Dept Urol, CH-3010 Bern, Switzerland

来源：

LANCET ONCOLOGY | 2014年 / 15卷 / 04期

关键词：

STEREOTACTIC BODY RADIOTHERAPY; DOSE-PER-FRACTION; POSTOPERATIVE RADIOTHERAPY; RADIATION-THERAPY; CERAMIDE; CANCER; ABSCOPAL; METASTASES; TRIAL; IRRADIATION;

D O I：

10.1016/S1470-2045(13)70569-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Renal-cell carcinoma is considered to be a radioresistant tumour, but this notion might be wrong. If given in a few (even single) fractions, but at a high fraction dose, stereotactic body radiotherapy becomes increasingly important in the management of renal-cell carcinoma, both in primary settings and in treatment of oligometastatic disease. There is an established biological rationale for the radiosensitivity of renal-cell carcinoma to stereotactic body radiotherapy based on the ceramide pathway, which is activated only when a high dose per fraction is given. Apart from the direct effect of stereotactic body radiotherapy on renal-cell carcinoma, stereotactic body radiotherapy can also induce an abscopal effect. This effect, caused by immunological processes, might be enhanced when targeted drugs and stereotactic body radiotherapy are combined. Therefore, rigorous, prospective randomised trials involving a multidisciplinary scientific panel are needed urgently.

引用

页码：E170 / E177

页数：8

共 63 条

[1]

Ahmed KA, 2012, FRONT ONCOL, V2, DOI [10.3389/fonc.2012.00172, 10.3389/fonc.2012.00215]

[2] Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma [J].

Beitler, JJ ;

Makara, D ;

Silverman, P ;

Lederman, G .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (06) :646-648

[3] Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy [J].

Berkovic, Patrick ;

De Meerleer, Gert ;

Delrue, Louke ;

Lambert, Bieke ;

Fonteyne, Valerie ;

Lumen, Nicolaas ;

Decaestecker, Karel ;

Villeirs, Geert ;

Vuye, Philippe ;

Ost, Piet .

CLINICAL GENITOURINARY CANCER, 2013, 11 (01) :27-32

[4]

Camphausen K, 2003, CANCER RES, V63, P1990

[5]

Chakrabarty Amit, 1994, In Vivo (Attiki), V8, P25

[6] Plasma membrane signaling induced by ionizing radiation [J].

Corre, Isabelle ;

Niaudet, Colin ;

Paris, Francois .

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2010, 704 (1-3) :61-67

[7] Radiation as an immunological adjuvant: current evidence on dose and fractionation [J].

Demaria, Sandra ;

Formenti, Silvia C. .

FRONTIERS IN ONCOLOGY, 2012, 2

[8] Treatment selection in metastatic renal cell carcinoma: expert consensus [J].

Escudier, Bernard ;

Szczylik, Cezary ;

Porta, Camillo ;

Gore, Martin .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (06) :327-337

[9]

FAIRLAMB DJ, 1981, CANCER-AM CANCER SOC, V47, P2102, DOI 10.1002/1097-0142(19810415)47:8<2102::AID-CNCR2820470833>3.0.CO

[10]

2-K

← 1 2 3 4 5 6 7 →